Emerging from the COVID-19 pandemic, pharmaceutical and biotech leaders face acute challenges related to patient recruitment, talent shortages, and the increasing complexity of clinical trials.
The report, R&D Trends in Pharma and Biotech, reflects today’s challenges and opportunities in bringing new therapies to market, as disclosed by more than 150 decision-making leaders at pharmaceutical and biotech companies around the world. Conducted by pharmaceutical market research firm Industry Standard Research (ISR), the survey asked respondents to consider the therapies in their pipelines, barriers to drug development, latest innovations in use, and the lingering effects and lessons of the COVID-19 pandemic.
Read more about the report and how to download it here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.